Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: JOEBT1 who wrote (1051)	10/7/1999 6:01:00 PM
From: Edscharp	Read Replies (1) \| Respond to of 2515

I listened to the replay twice. ImClone President and CEO, Dr. Samuel Waksal, in company with an outside patent counsel, were emphatic that ImClone's patent does not infringe upon Genentech's patent. Genentech's patent describes a different process and is a "method patent" (method of use) as opposed to ImClones "product patent". Waksal left no gray areas when he said that C225 will continue unimpeded and that there was no infringement upon any other company in the EGF receptor field. When asked, "Does ImClone have any reason at all to expect litigation?" Waksal answered tersely, "No". Waksal also said that Genentech was not working in this area (in the EGF receptor field). --- This was much ado about nothing. I expect a healthy rebound in the stock price.